Please provide your email address to receive an email when new articles are posted on . AMX0035 significantly improved C-peptide response at 48 weeks in a small group of adults with Wolfram syndrome.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced interim data from the ongoing Phase 2 HELIOS clinical trial of AMX0035 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback